# Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

> **NCT00500786** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG** · enrollment: 88 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **BIOLOGICAL:** CYT006-AngQb

## Key facts

- **NCT ID:** NCT00500786
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-09
- **Final completion:** 2007-04
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2012-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500786, "Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00500786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*